European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Similar documents
Cirrhosis is different from Fibrosis

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis

Screening for Portal Hypertension in Cirrhosis

Cirrhosis is the end stage of any chronic liver

Clinical Trials & Endpoints in NASH Cirrhosis

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Histological subclassification of cirrhosis based on histological haemodynamic correlation

Massimo Puoti SC Malattie Infettive ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA MILANO. Beyond HCV cure: reversibility of liver damage

Transient elastography in chronic viral liver diseases

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

HCV care after cure. This program is supported by educational grants from

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

ENCORE-PH Top-line Results

1. Introduction. Correspondence should be addressed to Daniela Cabibi;

B C Outlines. Child-Pugh scores

La gestione corrente dell infezione cronica da HCV: la progressione verso la cirrosi. Simona Landonio I Div Mal inf H Sacco Milano

Jong Young Choi, M.D.

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

Therapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH

Module 1 Introduction of hepatitis

Hepatology For The Nonhepatologist

Approved regimens for cirrhotic patients

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Beta-blockers in cirrhosis: Cons

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Patients with compensated cirrhosis: how to treat and follow-up

Hepatology for the Nonhepatologist

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Life After SVR for Cirrhotic HCV

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Transient elastography in chronic liver diseases of other etiologies

HEPATOLOGY ELSEWHERE. The Patient, the Doctor, and the System: Underdiagnosis and Undertreatment of Hepatitis B. Abstract.

Learning Objectives. After attending this presentation, participants will be able to:

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

RECURRENT HEPATITIS C CIRRHOSIS AFTER LIVER TRANSPLANTATION: A NATURAL HISTORY STUDY

Clinical Policy Title: Liver elastography

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Variceal bleeding. Mainz,

Advances in percutaneous ablation for hepatocellular carcinoma

MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

GR-MD-02 for Indication of NASH Cirrhosis: NASH-CX Clinical Trial Results

GR-MD-02 for Indication of NASH Cirrhosis

ANTIVIRAL THERAPY FOR HCV. Alfredo Alberti

Diagnosi e management non invasivo dell epatite cronica da HCV

HBV Therapy in Special Populations: Liver Cirrhosis

A. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017

Research Elastography: Liver

Quantitative Assessment of the Liver: Breath Tests. M. Shadab Siddiqui, M.D. Virginia Commonwealth University

Liver transplantation: Hepatocellular carcinoma

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano

New York State HCV Provider Webinar Series

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes

Hepatitis C Policy Discussion

Transient elastography the state of the art

Assessment of Liver Function: Implications for HCC Treatment

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

Causes of Liver Disease in US

Steatosi epatica ed HCV

Healthy Liver Cirrhosis

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

GI bleeding in chronic liver disease

Natural History of Chronic Hepatitis B

Worldwide Causes of HCC

Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

9th Paris Hepatitis Conference

in liver pathology? 2014 What s hot

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Hepatocellular Carcinoma: Diagnosis and Management

Paul Martin MD FACG. University of Miami

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

Worldwide Causes of HCC

Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients

The Value of Renal Artery Resistive Indices: Association with

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Biomarkers of PSC. Steve Helmke, Ph.D.

Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks

Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?

EASL-EORTC Guidelines

New York State HCV Provider Webinar Series. Overview of Fibrosis-Staging, Child s Pugh, MELD Scores

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Severity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Transcription:

supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza Calvaruso, MD, PhD Gastroenterology and Hepatology Unit, Di.Bi.M.I.S. University of Palermo Organized by :

The natural history of chronic liver disease Variceal hemorrhage Ascites Encephalopathy Development Jaundice Increasing liver fibrosis and neo-angiogenesis Chronic hepatitis of HCC Compensated cirrhosis Decompensated cirrhosis Death Esophageal Varices <5 5-10 12 > 12 Hepatic Venous Pressure Gradient (HVPG) (mm Hg)

Cirrhosis is a progression of stages of increasing severity and non-reversibility Biology: Metavir F4 Metavir F4 Ishak S 5Ishak S 6 6 Metavir F4 Ishak S 6 Metavir F4 Ishak S 6 Metavir F4 Ishak S6 Fibrogenesis & Scar X-linking angiogenesis Acellular scar Nodule size Insoluble scar & small nodules Scars & large nodules > 10 > 12 > 12 >5 HVPG: increasing vasodilatation Clinical: none none Varices formation Ascites (without VH) VH (+ ascites) Stage: Early stage cirrhosis Compensated (stage 1) Compensated (stage 2) Decompensat ed (stage 3) Decomp (stage 4) Stages according to D Amico et al, J Hepatol 2006;44: 217-31

Fig. 1 Histological classification of the severity of cirrhosis Size of the nodule Journal of Hepatology 2006 44, 111-117DOI: (10.1016/j.jhep.2005.07.036) Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. J Hepatol 2006;44:111-117. Thickness of septa

Fig. 3 to nodule size and septal Distribution of HVPG according thickness Journal of Hepatology 2006 44, 111-117DOI: (10.1016/j.jhep.2005.07.036) Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. J Hepatol 2006;44:111-117. Kumar M et Al, Aliment Pharmacol Ther 2008

The Laennec scoring system of cirrhosis 4a 4b 4c Thickness of septa / size of the nodule SU Kim, HJ Oh, IR. Wanless, S Lee, YN Park, J Hepatol 2012

Clinical relevance of scoring cirrhosis The Laennec scoring system for stratification of prognosis in patients with liver cirrhosis SU Kim, HJ Oh, IR. Wanless, S Lee, YN Park, J Hepatol 2012

Issues for histological assessment of liver fibrosis Histological scoring systems categorize architectural changes ISHAK category 6 ISHAK category 6 No quantitative progression across worsening categories CPA 27% CPA 12% No relation to amount of collagen (fibrosis) using trichrome/ reticulin stains which are general connective tissue stains Standish, 2006 Sirius red staining identifies primarily collagen the major constituent of fibrosis in chronic liver disease Puchtler, 1988

Correlation between area of fibrosis / Metavir stage Correlation between area of fibrosis /Ishak stage Area of fibrosis (%) METAVIR STAGE F0 F1 F2 F3 F4 Area of fibrosis by image analysis (mean + SEM) 2 + 0.14 3.4 + 0.25 5.8 + 1.7 14.7 + 3.77 25.1 + 4.44 Bedossa et al, Hepatology 2003 Standish et al, Gut 2006

Computer assisted Digital Image Analysis (DIA) Using segmentation of digital images to measure collagen proportionate area (CPA)

Spearman s r = 0.67; p < 0.001

Relationship between CPA and HVPG Calvaruso V et al, Hepatology 2009 Spearman s r = 0.605; p < 0.001

Invasive and non invasive evaluation of disease progression in chronic viral hepatitis Search for early predictor of decompensation Search for early predictor of HCC Search for predictor of progression rate to cirrhosis Spleen-related Non Invasive Indexes and Alghorythms Spleen stiffness measurement Liver stiffness measurement Serum markers: Direct/Indirect Serum markers:predictors of liver related outcomes Liver biopsy (PC or TJ): quantitative staging of CPA Cirrhosis without Cirrhosis with Early to advanced clinical clinical liver fibrosis manifestations manifestations HVPG < 5 mmhg HVPG 5-10 mmhg Liver Failure HVPG > 10-12 mmh Advanced chronic liver disease (ACLD)

CPS CPS HVPG mmhg Mean CPA (%) CPA (%) 5.0 5.0 7.0 13.0 13.8 (5.0 6.0) (5.0 6.5) (4.0 9.50) (8.3 16.4) (8.0 19.0) 6.0 6.0 8.5 23.0 18.8 (5.0 8.0) (5.0 8.0) (5.75 12.25) (17.0 33.7) (16.8 26.1) 0.132 0.243 0.097 < 0.001 0.009 CPA correlates with HVPG and predict decompensation in patients with recurrent HCV infection and liver cirrhosis Forty-three patients with HVPG measurement. CPA, collagen proportionate area; CPS, Child Pugh score; HVPG, hepatic venous pressure gradient; IQR, interquartile range. CPA correlates with HVPG CPA predicts decompensation p < 0.001 p = 0.042 by Log rank test Figure 1 Correlation betw een collagen proportionate area (CPA) and hepatic venous pressure gradient (HVPG) in 43 patients with recurrent hepatitis C V, virus-related Ishak stage 5 or 6 after liver transplantation. Calvaruso et al. Journal of Gastroenterology and Hepatology 2012

Clinical and histological associations with CSPH in 43 patients with recurrent HCV infection, and Ishak stage 5 or 6 after OLT Calvaruso V, et al. Journal of Gastroenterology and Hepatology 2012

Digital Image Analysis of Liver Collagen Predicts Clinical Outcome of Recurrent Hepatitis C Virus 1 Year After Liver Transplantation Manousou P et al, Liver International 2011

Manousou P et al, Liver International 2011

Collagen proportionate area (CPA) predicts clinical decompensation in patients with liver cirrhosis No clinical decompensation Clinical decompensation Tsochatzis E, et al. Journal of Hepatology 2014

Predictors of clinical decompensation at the time of baseline biopsy in 69 patients with cirrhosis Tsochatzis E, et al. Journal of Hepatology 2014

Collagen proportionate area (CPA) predicts portal hypertension and clinical decompensation in patients with HCV cirrhosis p = 0.026 by Log rank test Calvaruso V, et al. Alimentary and Pharmacological Therapy 2014

Free of events survival in patients with HCV cirrhosis according to CPA Calvaruso V et al. APT 2014.

Risk factors for liver decompensation (LD) in 118 patients with biopsy proven HCV cirrhosis, prospectively evaluated by CPA Calvaruso V et al. APT 2014.

Liver collagen in cirrhosis correlates with portal hypertension and liver dysfunction Forty-eight consecutive liver transplantation patients with established cirrhosis Hepatic venous pressure gradient (HVPG) and serum markers of liver failure determined prior to transplantation. CPA assessed in the explanted livers. CPA showed significant correlations with HVPG and with various surrogate markers of hepatic dysfunction including albumin, bilirubin, INR, MELD score and Child-Pugh score. CPA reliably discriminated HVPG 10 mmhg (AUROC 0.923, p < 0.001). Nielsen K, APMIS. 2014 Dec;122(12):1213-22

Take home messages Collagen continues to accumulate even when the biopsy stage is cirrhosis CPA measurement is a morphometric methods that continuously quantify collagen accumulation across the full spectrum of disease with no upper limit CPA scores HCV cirrhosis with a continuous scale and predicts clinical outcomes. Research agenda Evaluate the role of CPA, alone or combined with other tools, on the prediction of liver decompensation in liver disease of different etiology Evaluate if CPA could act as a histological standard for TE or other noninvasive markers of fibrosis.